The increasing global burden of cardiovascular diseases (CVD), driven by lifestyle-related risk factors and limited access to early diagnostics, has accelerated the demand for advanced, data-driven medical solutions. Against this backdrop, Japan’s cardiac marker tests market value is forecast to reach $19 million by 2036, according to GlobalData, a leading data and analytics company.

GlobalData’s report, “Cardiac Marker Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036,” reveals that Japan’s cardiac marker tests market accounted for around 20% of the Asia-Pacific (APAC) market in 2024, driven by the country’s aging population and high-quality healthcare infrastructure.

Cardio Diagnostics Holdings Inc., a US-based precision cardiovascular medicine company, recently announced that it has received a Japanese patent for a methodology that integrates epigenetic and genetic biomarkers with machine learning algorithms to enable early, non-invasive, and personalized risk assessment for CVD with improved accuracy.

Divya Soni, Medical Devices Analyst at GlobalData, comments: “The traditional approach to cardiovascular risk assessment often remains reactive, relying on symptoms and invasive procedures, falling short in identifying at-risk individuals early. An AI-powered platform can fill this gap through non-invasive, multi-omic tests that enhance clinical decision-making while reducing reliance on invasive procedures.”

The technology, exclusively licensed from the University of Iowa Research Foundation (UIRF), underpins Cardio Diagnostics’ flagship offerings such as Epi+Gen CHD and PrecisionCHD, which analyze patient-specific methylation and genetic patterns to provide actionable insights for both risk prediction and disease presence. These tools aim to shift the paradigm to proactive, data-driven care, empowering clinicians to make more informed decisions, especially in cases where traditional assessments may miss early warning signs.

Soni concludes: “With CVD remaining the leading cause of death globally, technologies that support proactive care are critical. This Japanese patent underscores the growing global recognition of AI-integrated diagnostics as the next frontier in preventive healthcare to deliver more personalized, accurate, and accessible cardiovascular care that transforms patient outcomes worldwide.”